• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    Lpath Inc. (LPTN)

    0.16 Up 0.00(0.06%) Feb 12, 3:06PM EST
    ProfileGet Profile for:
    Lpath Inc.
    4025 Sorrento Valley Boulevard
    San Diego, CA 92121
    United States - Map
    Phone: 858-678-0800
    Fax: 858-678-0900
    Website: http://www.lpath.com

    Index Membership:N/A
    Full Time Employees:25

    Business Summary 

    Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. The company is developing iSONEP, a humanized monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P), which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and is in Phase Ib/IIa clinical trials to treat retinal pigment epithelium detachment. It is also developing ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid S1P, which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma; and other angiogenic-related and inflammatory-oriented indications. In addition, the company develops Lpathomab, a mAb against lysophosphatidic acid, which is in pre-clinical stage for the treatment of neuropathic pain, traumatic brain injury, spinal cord injury, and fibrosis cancer. It has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Lpath Inc.

    Key Executives 
    Dr. Gary Woodnutt Ph.D., 59
    Chief Scientific Officer and Sr. VP
    Dr. Dario A. Paggiarino M.D., 59
    Chief Devel. Officer and Sr. VP
    Mr. Gary J. G. Atkinson , 63
    Chief Exec. Officer and Chief Financial Officer
    Mr. Roger A. Sabbadini Ph.D., 69
    Scientific Founder and VP
    Dr. Leigh Hsu Ph.D., M.B.A.,
    VP of Corp. Devel. & Strategy
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders